// App-Quantinova.ai

6045 : Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

Researchers

Presenter

  • Kevin J. Harrington

Principal Investigators

  • Martin David Forster

  • Christophe Le Tourneau

  • Jose Ariza

  • Shuquan Chen

  • Jonathan Greenberg

  • Kenji Hirotani

  • Eva Remenar

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • Institut Curie, Paris Cedex, France

  • UCLH - Cancer Clinical Trials Unit, London, United Kingdom

  • Daiichi Sankyo, Basking Ridge, NJ

  • Daiichi Sankyo, Basking Ridge, NJ

  • Daiichi Sankyo Co., Ltd., Tokyo, Japan

  • National Institute of Oncology, Budapest, Hungary

Locations

  • Japan

  • United Kingdom

  • United States

  • France

  • Hungary

Companies

  • Daiichi Sankyo Inc.

  • Daiichi Sankyo Compa

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Carboplatin

  • Patritumab

  • Erbitux

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II

Study Id's

  • NCT02633800

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved